
    
      First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
      Patients will proceed through a screening period, treatment period, and follow-up period of
      approximately 4 months' duration. There will be 4 dose cohorts including active drug and
      placebo dosing.
    
  